[18F]-Fluorodeoxyglucose positron emission tomography in children with neurofibromatosis type 1 and plexiform neurofibromas: Correlation with malignant transformation

Journal of Neuro-Oncology

Volumn 108, Issue 3, 2012, Pages 469-475

  Tsai, L L ^a,b   Drubach, L ^a   Fahey, F ^a   Irons, M ^a   Voss, S ^a   Ullrich, N J ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Malignant peripheral nerve sheath tumor; Neurofibromatosis type 1; PET; Plexiform neurofibroma; Transformation

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADULT; ANALYTICAL PARAMETERS; CANCER GRADING; CANCER SURGERY; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; DIAGNOSTIC VALUE; DISEASE COURSE; ELECTRONIC MEDICAL RECORD; FEMALE; FIBROMA; HISTOPATHOLOGY; HUMAN; INFORMATION RETRIEVAL; MALE; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MALIGNANT TRANSFORMATION; NEUROFIBROMA; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PLEXIFORM NEUROFIBROMA; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRESCHOOL CHILD; RADIODIAGNOSIS; REVIEW; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; STANDARDIZED UPTAKE VALUE; SYMPTOM; TUMOR BIOPSY; TUMOR VOLUME;

ADOLESCENT; ADULT; CELL TRANSFORMATION, NEOPLASTIC; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; INFANT; MALE; NERVE SHEATH NEOPLASMS; NEUROFIBROMA, PLEXIFORM; NEUROFIBROMATOSIS 1; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84864056181     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-012-0840-5     Document Type: Review

References (25)

1. Listernick R, Charrow J (1990) Neurofibromatosis type 1 in childhood. J Pediatr 116:845-853 (Pubitemid 20201691)
2. National Institutes of Health Concensus Development Confer-ence Statement: neurofibromatosis (1988) Neurofibromatosis 1:172-178
3. Widemann BC (2009) Current status of sporadic and neurofi-bromatosis type 1-associated malignant peripheral nerve sheath tumors. Curr Oncol Rep 11:322-328
4. Brems H, Beert E, de Ravel T, Legius E (2009) Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1. Lancet Oncol 10:508-515
5. Gottfried ON, Viskochil DH, Couldwell WT (2010) Neurofi-bromatosis type 1 and tumorigenesis: molecular mechanisms and therapeutic implications. Neurosurg Focus 28:E8
6. Tucker T, Wolkenstein P, Revuz J, Zeller J, Friedman JM (2005) Association between benign and malignant peripheral nerve sheath tumors in NF1. Neurology 65:205-211 (Pubitemid 41022362)
7. Ferner RE, Gutmann DH (2002) International consensus state-ment on malignant peripheral nerve sheath tumors in neurofi-bromatosis. Cancer Res 62:1573-1577 (Pubitemid 34407825)
8. Hoh CK, Hawkins RA, Glaspy JA, Dahlbom M, Tse NY, Hoff-man EJ, Schiepers C, Choi Y, Rege S, Nitzsche E et al (1993) Cancer detection with whole-body PET using 2-[18F] fluoro-2-deoxy-D-glucose. J Comput Assist Tomogr 17:582-589 (Pubitemid 23206739)
9. Wong TZ, van der Westhuizen GJ, Coleman RE (2002) Positron emission tomography imaging of brain tumors. Neuroimaging Clin N Am 12:615-626 (Pubitemid 36015495)
10. Cardona S, Schwarzbach M, Hinz U, Dimitrakopoulou-Strauss A, Attigah N (2003) Mechtersheimer section sign G, Lehnert T: evaluation of F18-deoxyglucose positron emission tomography (FDG-PET) to assess the nature of neurogenic tumours. Eur J Surg Oncol 29:536-541 (Pubitemid 37009972)
11. Fisher MJ, Basu S, Dombi E, Yu JQ, Widemann BC, Pollock AN, Cnaan A, Zhuang H, Phillips PC, Alavi A (2008) The role of [18F]-fluorodeoxyglucose positron emission tomography in pre-dicting plexiform neurofibroma progression. J Neurooncol 87:165-171
12. Brenner W, Friedrich RE, Gawad KA, Hagel C, von Deimling A, de Wit M, Buchert R, Clausen M, Mautner VF (2006) Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours. Eur J Nucl Med Mol Imaging 33:428-432
13. Ferner RE, Golding JF, Smith M, Calonje E, Jan W, Sanjaya-nathan V, O'Doherty M (2008) [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study. Ann Oncol 19:390-394 (Pubitemid 351201726)
14. Valeyrie-Allanore L, Ortonne N, Lantieri L, Ferkal S, Wechsler J, Bagot M, Wolkenstein P (2008) Histopathologically dysplastic neurofibromas in neurofibromatosis 1: diagnostic criteria, preva-lence and clinical significance. Br J Dermatol 158:1008-1012 (Pubitemid 351521455)
15. Lin BT, Weiss LM, Medeiros LJ (1997) Neurofibroma and cel-lular neurofibroma with atypia: a report of 14 tumors. Am J Surg Pathol 21:1443-1449 (Pubitemid 27528254)
16. Van Vliet M, Kliffen M, Krestin GP, van Dijke CF (2009) Soft tissue sarcomas at a glance: clinical, histological, and MR imaging features of malignant extremity soft tissue tumors. Eur Radiol 19:1499-1511
17. Spurlock G, Knight SJ, Thomas N, Kiehl TR, Guha A, Up-adhyaya M (2010) Molecular evolution of a neurofibroma to malignant peripheral nerve sheath tumor (MPNST) in an NF1 patient: correlation between histopathological, clinical and molecular findings. J Cancer Res Clin Oncol 136:1869-1880
18. Matsumine A, Kusuzaki K, Nakamura T, Nakazora S, Niimi R, Matsubara T, Uchida K, Murata T, Kudawara I, Ueda T, Naka N, Araki N, Maeda M, Uchida A (2009) Differentiation between neurofibromas and malignant peripheral nerve sheath tumors in neurofibromatosis 1 evaluated by MRI. J Cancer Res Clin Oncol 135:891-900
19. Korf BR (1999) Plexiform neurofibromas. Am J Med Genet 89:31-37 (Pubitemid 30033174)
20. Bredella MA, Torriani M, Hornicek F, Ouellette HA, Plamer WE, Williams Z, Fischman AJ, Plotkin SR (2007) Value of PET in the assessment ofpatients with neurofibromatosis type 1. AJR Am J Roentgenol 189:928-935 (Pubitemid 47479778)
21. Warbey VS, Ferner RE, Dunn JT, Calonje E, O'Doherty MJ (2009) [18F] FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1. Eur J Nucl Med Mol Imaging 36:751-757
22. Moharir M, London K, Howman-Giles R, North K (2010) Utility of positron emission tomography for tumour surveillance in children with neurofibromatosis type 1. Eur J Nucl Med Mol Imaging 37:1309-1317
23. Basu S, Nair N (2006) Potential clinical role of FDG-PET in detecting sarcomatous transformation in von Recklinghausen's disease: a case study and review of the literature. J Neurooncol 80:91-95 (Pubitemid 44473267)
24. Karabatsou K, Kiehl TR, Wilson DM, Hendler A, Guha A (2009) Potential role of 18fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating benign neurofibroma from malignant peripheral nerve sheath tumor associated with neurofibromatosis 1. Neurosurgery 65:A160-A170
25. Shahid KR, Amrami KK, Esther RJ, Lowe VJ, Spinner RJ (2011) False-negative fluorine-18 fluorodeoxyglucose positron emission tomography of a malignant peripheral nerve sheath tumor arising from a plexiform neurofibroma in the setting of neurofibromatosis type 1. J Surg Orthop Adv 20:132-135